Leuprorelin: Difference between revisions

Leuprorelin
Clinical data
Pregnancy; category	X;
Routes of; administration	Implant / Injection
ATC code	L02AE02 (WHO) ;
Legal status
Legal status	℞-only;
Pharmacokinetic data
Elimination half-life	3 hours
Excretion	Renal
Identifiers
	IUPAC name N-[1-[[1-[[1-[[1-[[1-[[1-[[5-; (diaminomethylideneamino)-1-; [2-(ethylcarbamoyl)pyrrolidin-1-yl]-; 1-oxo-pentan-2-yl]carbamoyl]-; 3-methyl-butyl]carbamoyl]-3-methyl-; butyl]carbamoyl]-2-(4-hydroxyphenyl); ethyl]carbamoyl]-2-hydroxy-ethyl]; carbamoyl]-2-(1H-indol-3-yl)ethyl]; carbamoyl]-2-(3H-imidazol-4-yl)ethyl]-; 5-oxo-pyrrolidine-2-carboxamide;
CAS Number	53714-56-0;
PubChem CID	441410;
DrugBank	BTD00009;
CompTox Dashboard (EPA)	DTXSID50872411 ;
ECHA InfoCard	100.161.466
Chemical and physical data
Formula	C59H84N16O12
Molar mass	1209.4 g/mol g·mol−1

Browse history interactively

← Previous edit Next edit →

Content deleted Content added

VisualWikitext

Inline

Revision as of 10:57, 18 September 2006

File:Leuprolide.gif

Lupron Logo

Leuprolide/Leuprorelin is a gonadotropin-releasing hormone agonist (GnRH agonist). By causing constant stimulation of the pituitary GnRH receptors, it initially causes stimulation (flare), but thereafter decreases pituitary secretion (downregulation) of gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH). Like other GnRH agonists, leuprolide may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, estrogen-dependent conditions (such as endometriosis or uterine fibroids), to treat precocious puberty, and to control ovarian stimulation in IVF. It is also considered a possible treatment for paraphilias..^[1]

Leuprolide acetate is marketed by Bayer AG under the brand name Viadur, by Sanofi-Aventis under the brand name Eligard, and by TAP Pharmaceuticals under the brand name Lupron. It is available as a slow-release implant or sub-cutaneous/intramuscular injection.

External links

Lupron Depot (manufacturer's website)
Lupron® Injection (package insert from abbott)
Trandolapril (patient information)

This medical treatment–related article is a stub. You can help Wikipedia by expanding it.

Template:Sex hormones

^ Saleh FM, Niel T, Fishman MJ (2004). "Treatment of paraphilia in young adults with leuprolide: a preliminary case report series". Journal of Forensic Sciences. 49 (6): 6.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[1] Saleh FM, Niel T, Fishman MJ (2004). "Treatment of paraphilia in young adults with leuprolide: a preliminary case report series". Journal of Forensic Sciences. 49 (6): 6.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[1]

@@ Line 17: / Line 17: @@
 <!-- FAIR USE of Leuprolide.gif: see image description page at http://en.wikipedia.org/wiki/Image:Leuprolide.gif for rationale -->
-'''Leuprolide/Leuprorelin''' is a [[gonadotropin-releasing hormone agonist]] ([[GnRH agonist]]).  By causing constant stimulation of the [[pituitary]] GnRH receptors, it initially causes stimulation (flare), but thereafter decreases pituitary secretion ([[downregulation]]) of gonadotropins [[luteinizing hormone]] (LH) and [[follicle stimulating hormone]] (FSH).  Like other GnRH agonists, leuprolide may be used in the treatment of hormone-responsive cancers such as [[prostate cancer]] or [[breast cancer]], estrogen-dependent conditions (such as [[endometriosis]] or [[uterine fibroids]]), to treat [[precocious puberty]], and to control ovarian stimulation in [[IVF]].  It is also considered a possible treatment for [[paraphilias]].
+'''Leuprolide/Leuprorelin''' is a [[gonadotropin-releasing hormone agonist]] ([[GnRH agonist]]).  By causing constant stimulation of the [[pituitary]] GnRH receptors, it initially causes stimulation (flare), but thereafter decreases pituitary secretion ([[downregulation]]) of gonadotropins [[luteinizing hormone]] (LH) and [[follicle stimulating hormone]] (FSH).  Like other GnRH agonists, leuprolide may be used in the treatment of hormone-responsive cancers such as [[prostate cancer]] or [[breast cancer]], estrogen-dependent conditions (such as [[endometriosis]] or [[uterine fibroids]]), to treat [[precocious puberty]], and to control ovarian stimulation in [[IVF]].  It is also considered a possible treatment for [[paraphilias]]..<ref>{{cite journal | author=Saleh FM, Niel T, Fishman MJ | title=Treatment of paraphilia in young adults with leuprolide: a preliminary case report series | journal=Journal of Forensic Sciences | year=2004 | pages=6 | volume=49 | issue=6}}</ref>
 Leuprolide acetate is marketed by [[Bayer|Bayer AG]] under the brand name '''Viadur''', by [[Sanofi-Aventis]] under the brand name '''Eligard''', and by [[TAP Pharmaceuticals]] under the brand name '''Lupron'''. It is available as a slow-release implant or sub-cutaneous/intramuscular injection.